AbCellera Biologics Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
AbCellera Biologics Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2024.
  • AbCellera Biologics Inc. Debt-to-equity for the quarter ending September 30, 2024 was 28.7 %, a 9.19% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 28.7 +2.42 +9.19% Sep 30, 2024
Q2 2024 28.4 +3 +11.8% Jun 30, 2024
Q1 2024 28.8 +2.67 +10.2% Mar 31, 2024
Q4 2023 27.4 -0.68 -2.42% Dec 31, 2023
Q3 2023 26.3 -2.65 -9.15% Sep 30, 2023
Q2 2023 25.4 -3.64 -12.5% Jun 30, 2023
Q1 2023 26.1 +0.08 +0.31% Mar 31, 2023
Q4 2022 28.1 +5.82 +26.2% Dec 31, 2022
Q3 2022 29 +8.75 +43.3% Sep 30, 2022
Q2 2022 29.1 Jun 30, 2022
Q1 2022 26 Mar 31, 2022
Q4 2021 22.2 Dec 31, 2021
Q3 2021 20.2 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.